For example, antibodies that 1) have been implicated in lung allograft injury following a lung transplant (ACHRG); 2) are against soluble factors that play a role in lung inflammation (BAFF) (24, 25); 3) are against the cytoskeletal structure of the alveolar epithelium (cytokeratin 19); and 4) are elevated during tissue damage (NSE, SCCA, and Beta-glucuronidase) (26–31) have been noted to have higher titers in patients with pneumonitis than in patients without irAEs at the time of toxicity. The gene discussed is ENO2; the disease is pneumonitis.